BIOSYENT INC (RX.CA) Stock Overview
Canada - TSX-V:RX - CA0906901081 - Common Stock
RX.CA Key Statistics, Chart & Performance
The current stock price of RX.CA is 11.56 CAD. In the past month the price decreased by -3.95%. In the past year, price increased by 5.09%.
RX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.73 | 3.39B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 2.52B | ||
| CRON.CA | CRONOS GROUP INC | 51.71 | 1.39B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.93 | 822.33M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 580.96M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 502.95M | ||
| TSND.CA | TERRASCEND CORP | N/A | 447.39M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 446.06M | ||
| HITI.CA | HIGH TIDE INC | N/A | 438.88M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 25.3 | 409.93M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 349.26M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 263.08M |
Related stock screener links
About RX.CA
Company Profile
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Company Info
BIOSYENT INC
2476 Argentia Road, Suite 402
Mississauga ONTARIO L5N 6M1 CA
CEO: Rene Goehrum
Employees: 0
Phone: 18884390013
BIOSYENT INC / RX.CA FAQ
What is the stock price of BIOSYENT INC today?
The current stock price of RX.CA is 11.56 CAD.
What is the ticker symbol for BIOSYENT INC stock?
The exchange symbol of BIOSYENT INC is RX and it is listed on the TSX Venture Exchange exchange.
On which exchange is RX.CA stock listed?
RX.CA stock is listed on the TSX Venture Exchange exchange.
What is the price forecast or stock price prediction for BIOSYENT INC stock?
7 analysts have analysed RX.CA and the average price target is 13.26 CAD. This implies a price increase of 14.71% is expected in the next year compared to the current price of 11.56. Check the BIOSYENT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOSYENT INC worth?
BIOSYENT INC (RX.CA) has a market capitalization of 132.71M CAD. This makes RX.CA a Micro Cap stock.
How many employees does BIOSYENT INC have?
BIOSYENT INC (RX.CA) currently has 0 employees.
What are the support and resistance levels for BIOSYENT INC (RX.CA) stock?
BIOSYENT INC (RX.CA) has a support level at 11.5 and a resistance level at 11.67. Check the full technical report for a detailed analysis of RX.CA support and resistance levels.
Is BIOSYENT INC (RX.CA) expected to grow?
The Revenue of BIOSYENT INC (RX.CA) is expected to grow by 17.51% in the next year. Check the estimates tab for more information on the RX.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOSYENT INC (RX.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RX.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RX.CA, evaluating the profitability, health, valuation and growth aspects
- BIOSYENT INC (RX.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOSYENT INC (RX.CA) Sales and EPS estimates to see what analysts future expectations are.
- BIOSYENT INC (RX.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOSYENT INC (RX.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOSYENT INC (RX.CA) Stock Chart to make your own analysis
- BIOSYENT INC (RX.CA) Latest news and press-releases to stay up to date.
Does BIOSYENT INC (RX.CA) stock pay dividends?
BIOSYENT INC (RX.CA) has a dividend yield of 1.67%. The yearly dividend amount is currently 0.18. Check the full fundamental report for a detailed analysis of RX.CA dividend history, reliability and sustainability.
When does BIOSYENT INC (RX.CA) report earnings?
BIOSYENT INC (RX.CA) will report earnings on 2025-11-18.
What is the Price/Earnings (PE) ratio of BIOSYENT INC (RX.CA)?
The PE ratio for BIOSYENT INC (RX.CA) is 18.65. This is based on the reported non-GAAP earnings per share of 0.62 and the current share price of 11.56 CAD. Check the full fundamental report for a full analysis of the valuation metrics for RX.CA.
RX.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RX.CA. When comparing the yearly performance of all stocks, RX.CA is a bad performer in the overall market: 74.95% of all stocks are doing better.
RX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA. RX.CA scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
RX.CA Financial Highlights
Over the last trailing twelve months RX.CA reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 14.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.43% | ||
| ROA | 18.29% | ||
| ROE | 21.72% | ||
| Debt/Equity | 0.02 |
RX.CA Forecast & Estimates
7 analysts have analysed RX.CA and the average price target is 13.26 CAD. This implies a price increase of 14.71% is expected in the next year compared to the current price of 11.56.
For the next year, analysts expect an EPS growth of 20.96% and a revenue growth 17.51% for RX.CA